85 related articles for article (PubMed ID: 1327941)
1. [In vivo and in vitro effects of GnRH analogs on ovarian Leydig cell tumor].
Emons G; Ortmann O; Pahwa GS; Löhrs U; Wetterling T; Dilling H; Oberheuser F; Knuppen R
Geburtshilfe Frauenheilkd; 1992 Aug; 52(8):487-93. PubMed ID: 1327941
[TBL] [Abstract][Full Text] [Related]
2. Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature.
Klotz RK; Müller-Holzner E; Fessler S; Reimer DU; Zervomanolakis I; Seeber B; Mattle V; Wildt L
Exp Clin Endocrinol Diabetes; 2010 May; 118(5):291-7. PubMed ID: 20198556
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
4. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours.
Pascale MM; Pugeat M; Roberts M; Rousset H; Déchaud H; Dutrieux-Berger N; Tourniaire J
Clin Endocrinol (Oxf); 1994 Nov; 41(5):571-6. PubMed ID: 7828344
[TBL] [Abstract][Full Text] [Related]
5. Long-term suppression of a testosterone-producing ovarian tumour by oestrogen/progestogen therapy.
Drife JO; O'Malley BP; Rosenthal FD
Clin Endocrinol (Oxf); 1987 Jul; 27(1):121-4. PubMed ID: 3115633
[TBL] [Abstract][Full Text] [Related]
6. Sertoli-Leydig cell tumors: hormonal profile after dynamic test with GnRH analogue: triptorelin represents a useful tool to evaluate tumoral hyperandrogenism.
Turra J; Granzotto M; Gallea M; Faggian D; Conte L; Litta P; Vettor R; Mioni R
Gynecol Endocrinol; 2015 Jan; 31(1):18-21. PubMed ID: 25299229
[TBL] [Abstract][Full Text] [Related]
7. Hilus cell pathology and hirsutism.
McLellan AR; Mowat A; Cordiner J; Beastall GH; Wallace AM; Connell JM; Davies DL
Clin Endocrinol (Oxf); 1990 Feb; 32(2):203-12. PubMed ID: 2112066
[TBL] [Abstract][Full Text] [Related]
8. Short term administration of gonadotropin-releasing hormone analog to a patient with a testosterone-secreting ovarian tumor.
Kennedy L; Traub AI; Atkinson AB; Sheridan B
J Clin Endocrinol Metab; 1987 Jun; 64(6):1320-2. PubMed ID: 3106399
[TBL] [Abstract][Full Text] [Related]
9. Endocrine investigations in two cases of feminizing Leydig cell tumour.
Valensi P; Coussieu C; Kemeny JL; Attali JR; Amouroux J; Sebaoun J
Acta Endocrinol (Copenh); 1987 Jul; 115(3):365-72. PubMed ID: 3113148
[TBL] [Abstract][Full Text] [Related]
10. Endocrinological aspects of a Sertoli-Leydig cell tumour. Case report.
Van Dessel T; Heineman MJ
Br J Obstet Gynaecol; 1990 Nov; 97(11):1054-60. PubMed ID: 2123713
[No Abstract] [Full Text] [Related]
11. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
[TBL] [Abstract][Full Text] [Related]
12. Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour.
Picón MJ; Lara JI; Sarasa JL; Recasens JD; Clouet R; Gonzalo MA; Rovira A
Eur J Endocrinol; 2000 Jun; 142(6):619. PubMed ID: 10822225
[TBL] [Abstract][Full Text] [Related]
13. [Endocrine profile and electron microscopic study of ovarian androblastoma].
Inoue S; Fukuda O; Koyama N; Furuki Y; Munemura M; Maeyama M; Mizumoto J; Miyayama Y
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Aug; 36(8):1155-62. PubMed ID: 6096462
[TBL] [Abstract][Full Text] [Related]
14. Androgen response in polycystic ovarian syndrome to FSH treatment after LHRH agonist suppression.
Hamori M; Zwirner M; Clédon P; Tinneberg HR
Int J Fertil; 1992; 37(3):171-5. PubMed ID: 1355764
[TBL] [Abstract][Full Text] [Related]
15. Testosterone/androstenedione ratio in the evaluation of women with ovarian androgen excess.
Wiebe RH; Morris CV
Obstet Gynecol; 1983 Mar; 61(3):279-84. PubMed ID: 6296743
[TBL] [Abstract][Full Text] [Related]
16. "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis.
Meldrum DR; Chang RJ; Lu J; Vale W; Rivier J; Judd HL
J Clin Endocrinol Metab; 1982 May; 54(5):1081-3. PubMed ID: 6801075
[TBL] [Abstract][Full Text] [Related]
17. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
[TBL] [Abstract][Full Text] [Related]
19. Effects of gonadotropin-releasing hormone analogues on ovarian epithelial tumors.
Adelson MD; Reece MT
Clin Obstet Gynecol; 1993 Sep; 36(3):690-700. PubMed ID: 8403615
[No Abstract] [Full Text] [Related]
20. Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist.
Rolandi E; Franceschini R; Giberti C; Brancadoro T; Martorana G; Barreca T
Horm Res; 1988; 30(1):22-5. PubMed ID: 2975631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
